Back in favour, HCQ could spur India’s Covid-19 diplomacy

With hydroxychloroquine regaining its credibility after WHO restarted its trials and the authors of a Lancet study slamming it falling into controversy, India’s Covid-19 diplomacy, of which supply of HCQ to dozens of countries was an important part, could gain ground again.